Home>Topics>Companies>King Pharmaceuticals

King Pharmaceuticals KG

  1. All
  2. Commentary
  3. Stock Reports
  4. Fund Reports
  5. ETF Reports
  6. Headlines
    1. Prozac Nation, Street Version

      Headlines

      Fri, 25 Jul 2014

      sessions, expanded 49%. During the conference call, management mentioned that contracts with Novartis NVS and King Pharmaceuticals KG have started contributing to this segment. Revenues from the prepackaged medications segment, which accounts

    2. Pfizer: Pfine With Or Without AstraZeneca

      Headlines

      Mon, 23 Jun 2014

      Pfizer also includes assets of former independent firms Alacer Corporation, Ayerst, Excaliard Pharmaceuticals, King Pharmaceuticals , NextWave Pharmaceuticals, Parke-Davis, Searle, Sugen and Upjohn. Pfizer also owns a significant stake in

    3. XPH SPDR S&P Pharmaceuticals ETF ETF Analysis, Report, Research, 5 Star Rating – Morningstar

      ETF Reports

      Mon, 5 May 2014

      TEVA acquisition of German generic drugmaker Ratiopharm Group International, Sanofi's SNY acquisition of Genzyme, Merck of Germany's takeover of Millipore, and Pfizer's PFE acquisition of pain drugmaker King Pharmaceuticals .

    4. New Morningstar Analyst Report for Zoetis Inc

      Stock Reports

      Mon, 31 Mar 2014

      Zoetis has recently seen margin improvement due to synergies from the acquisitions of Fort Dodge (Wyeth) and Alpharma ( King Pharma ) and from Pfizer's companywide cost-reduction program. Management expects continued margin expansion as a result

    5. New Morningstar Analyst Report for Zoetis Inc

      Stock Reports

      Mon, 31 Mar 2014

      the acquisitions of Fort Dodge (Wyeth) and Alpharma ( King Pharma ) and from Pfizer's companywide cost-reduction program ..... health-care firm, such as Pfizer's acquisition of King Pharma (Alpharma). The only data point worth noting is the

    6. RXL ProShares Ultra Health Care ETF Analysis, Report, Research, 5 Star Rating – Morningstar

      ETF Reports

      Tue, 18 Sep 2012

      acquisition of Genzyme, Merck of Germany's takeover of Millipore, and Pfizer's PFE acquisition of pain-drug maker King Pharmaceuticals . In our view, an ETF can help health-care investors diversify away company-specific risks. Granted, all

    7. PPH Market Vectors Pharmaceutical ETF ETF Analysis, Report, Research, 5 Star Rating – Morningstar

      ETF Reports

      Tue, 21 Aug 2012

      acquisition of Genzyme, Merck of Germany's takeover of Millipore, and Pfizer's PFE acquisition of pain-drug maker King Pharmaceuticals . In our view, an ETF makes a lot of sense for health-care investors. No matter how deep your knowledge of

    8. Covidien to Spin Out Pharmaceutical Business

      Commentary

      Thu, 15 Dec 2011

      based on our review of some of its peers, such as Endo Pharmaceuticals ENDP, as well as the recent acquisition of King Pharmaceuticals by Pfizer PFE and Bristol-Myers Squibb's BMY sale of its imaging business (which included branded Cardiolite

    9. Diamond Hill Small Cap Fund First Quarter Commentary

      Headlines

      Tue, 24 May 2011

      deals for food producer Del Monte Foods and drug maker King Pharmaceuticals closed. Del Monte was taken private by a KKR led consortium for $19 cash per share and King was acquired by Pfizer, Inc. for $14.25 per share

    « Prev12345Next »
    Content Partners